<DOC>
	<DOCNO>NCT01934140</DOCNO>
	<brief_summary>The purpose study evaluate long-term antibody persistence 6 , 7 , 8 , 9 10 year post-administration MenACWY-TT conjugate vaccine compare Mencevax ACWY give healthy subject 11 55 year age . In addition , safety immunogenicity booster dose MenACWY-TT vaccine administer eligible subject 10 year primary vaccination evaluate . All Filipino subject receive primary vaccination primary vaccination study 107386 ( NCT00356369 ) invite enrol long-term follow booster phase . No new subject enrol .</brief_summary>
	<brief_title>Study Evaluate Long-term Antibody Persistence GlaxoSmithKline ( GSK ) Biologicals ' MenACWY-TT Vaccine ( GSK134612 ) Versus Mencevax ACWY Healthy Adolescents Adults Booster Response MenACWY-TT Vaccine Administered 10 Years Post-primary Vaccination</brief_title>
	<detailed_description />
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>All subject must satisfy follow criterion study entry persistence phase : Subjects , opinion investigator , comply requirement protocol . Or /and subject ' parent ( ) /Legally Acceptable Representative ( ) [ LAR ( ) ] , opinion investigator , comply requirement protocol . A male female include 17 66 year age time entry present study . Has complete vaccination phase vaccination study MENACWYTT015 . In alignment local law regulation , write informed consent obtain parents/LAR ( ) subject write informed assent obtain subject subject le 18 year age , write informed consent obtain subject subject achieve 18th birthday . The subject ≥18 year age time enrollment sign inform consent form , even parent/ LAR previously sign ICF subject reach legal age consent . Healthy subject establish medical history historydirected physical examination enter study . All subject must satisfy follow additional criterion prior entry booster phase : Female subject nonchildbearing potential may enrol study . Nonchildbearing potential define premenarche , current tubal ligation , hysterectomy , ovariectomy postmenopause . Female subject childbearing potential may enrol study , subject : practiced adequate contraception 30 day prior vaccination , negative pregnancy test day vaccination , agree continue adequate contraception entire treatment period 2 month completion vaccination series . Child care . Previous vaccination meningococcal polysaccharide conjugate vaccine outside study MENACWYTT015 . History meningococcal disease due serogroup A , C , W135 Y . Any confirm suspected immunosuppressive immunodeficient condition , include Human Immunodeficiency Virus ( HIV ) infection , base medical history physical examination . Major congenital defect serious chronic illness . Family history congenital hereditary immunodeficiency . History chronic alcohol consumption and/or drug abuse . Additional exclusion criterion booster phase Month 120 study entry ( checked Month 120 ) subject Use investigational nonregistered product study vaccine within 30 day precede booster dose study vaccine , plan use followup period . Chronic administration ( defined 14 day total ) immunosuppressant immunemodifying drug within six month prior booster vaccine dose . Inhaled topical steroid allow . Administration vaccine foreseen study protocol period start 30 day booster dose study vaccine plan administration within 30 day vaccination ( day vaccination consider Day 0 ) , exception license inactivated influenza vaccine . Administration immunoglobulins and/or blood product within three month precede booster vaccination plan administration followup period . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational vaccine/product . Previous vaccination tetanus toxoid within last month . History reaction hypersensitivity likely exacerbate component vaccine . History neurological disorder seizure , include GuillainBarré syndrome ( GBS ) . History simple , single febrile seizure permit . Acute disease and/or fever time enrollment . Fever define temperature ≥ 37.5°C oral , axillary tympanic route , ≥ 38.0°C rectal route . The preferred route record temperature study oral . Subjects minor illness without fever may , enrol discretion investigator . Pregnant lactate female . Female plan become pregnant planning discontinue contraceptive precaution .</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>66 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Adults</keyword>
	<keyword>Safety</keyword>
	<keyword>Neisseria meningitidis</keyword>
	<keyword>Booster response</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Adolescents</keyword>
	<keyword>Serogroups A , C , W-135 , Y</keyword>
	<keyword>long-term antibody persistence</keyword>
</DOC>